Cancer Research Aziza Shad Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Andersen, M. H.
Right arrow Articles by thor Straten, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Andersen, M. H.
Right arrow Articles by thor Straten, P.
[Cancer Research 61, 5964-5968, August 15, 2001]
© 2001 American Association for Cancer Research

Advances in Brief

Spontaneous Cytotoxic T-Cell Responses against Survivin-derived MHC Class I-restricted T-Cell Epitopes in Situ As Well As ex Vivo in Cancer Patients1

Mads Hald Andersen2, Lars Ø. Pedersen, Barbara Capeller, Eva-Bettina Bröcker, Jürgen C. Becker and Per thor Straten

Department of Tumor Cell Biology, Danish Cancer Society, 2100 Copenhagen, Denmark [M. H. A., L. Ø. P., P. t. S.], and Departments of Dermatology [J. C. B., E-B. B.] and Gynecology [B. C.], University of Würzburg, D-97080 Würzburg, Germany

Recent advances in therapeutic tumor vaccinations necessitate the identification of broadly expressed, immunogenic tumor antigens that are not prone to immune selection. To this end, the human inhibitor of apoptosis, survivin, is a prime candidate because it is expressed in most human neoplasms but not in normal, differentiated tissues. Here, we demonstrate spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in breast cancer, leukemia, and melanoma patients both in situ as well as ex vivo. Moreover, survivin-reactive T cells isolated by magnetic beads coated with MHC/peptide complexes were cytotoxic against HLA-matched tumors of different tissue types. Being a universal tumor antigen, survivin may serve as a widely applicable target for anticancer immunotherapy.




This article has been cited by other articles:


Home page
 Int ImmunolHome page
W. H. Shingler, P. Chikoti, S. M. Kingsman, and R. Harrop
Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4
Int. Immunol., August 1, 2008; 20(8): 1057 - 1066.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Schaue, B. Comin-Anduix, A. Ribas, L. Zhang, L. Goodglick, J. W. Sayre, A. Debucquoy, K. Haustermans, and W. H. McBride
T-Cell Responses to Survivin in Cancer Patients Undergoing Radiation Therapy
Clin. Cancer Res., August 1, 2008; 14(15): 4883 - 4890.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
X.-F. Wang, J. Kerzerho, O. Adotevi, H. Nuyttens, C. Badoual, G. Munier, S. Oudard, S. Tu, E. Tartour, and B. Maillere
Comprehensive Analysis of HLA-DR- and HLA-DP4-Restricted CD4+ T Cell Response Specific for the Tumor-Shared Antigen Survivin in Healthy Donors and Cancer Patients
J. Immunol., July 1, 2008; 181(1): 431 - 439.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. H. Andersen, I. M. Svane, J. C. Becker, and P. t. Straten
The Universal Character of the Tumor-Associated Antigen Survivin
Clin. Cancer Res., October 15, 2007; 13(20): 5991 - 5994.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Parmiani, V. Russo, A. Marrari, G. Cutolo, C. Casati, L. Pilla, C. Maccalli, L. Rivoltini, and C. Castelli
Universal and Stemness-Related Tumor Antigens: Potential Use in Cancer Immunotherapy
Clin. Cancer Res., October 1, 2007; 13(19): 5675 - 5679.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. E. Krambeck, H. Dong, R. H. Thompson, S. M. Kuntz, C. M. Lohse, B. C. Leibovich, M. L. Blute, T. J. Sebo, J. C. Cheville, A. S. Parker, et al.
Survivin and B7-H1 Are Collaborative Predictors of Survival and Represent Potential Therapeutic Targets for Patients with Renal Cell Carcinoma
Clin. Cancer Res., March 15, 2007; 13(6): 1749 - 1756.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Grube, S. Moritz, E. C. Obermann, K. Rezvani, A. Mackensen, R. Andreesen, and E. Holler
CD8+ T cells Reactive to Survivin Antigen in Patients with Multiple Myeloma
Clin. Cancer Res., February 1, 2007; 13(3): 1053 - 1060.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. M. Coughlin, M. D. Fleming, R. G. Carroll, B. R. Pawel, M. D. Hogarty, X. Shan, B. A. Vance, J. N. Cohen, S. Jairaj, E. M. Lord, et al.
Immunosurveillance and Survivin-Specific T-Cell Immunity in Children With High-Risk Neuroblastoma
J. Clin. Oncol., December 20, 2006; 24(36): 5725 - 5734.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Casati, C. Camisaschi, F. Rini, F. Arienti, L. Rivoltini, F. Triebel, G. Parmiani, and C. Castelli
Soluble Human LAG-3 Molecule Amplifies the In vitro Generation of Type 1 Tumor-Specific Immunity.
Cancer Res., April 15, 2006; 66(8): 4450 - 4460.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Mayr, D. M. Kofler, H. Buning, D. Bund, M. Hallek, and C.-M. Wendtner
Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells
Blood, November 1, 2005; 106(9): 3223 - 3226.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Mayr, D. Bund, M. Schlee, A. Moosmann, D. M. Kofler, M. Hallek, and C.-M. Wendtner
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes
Blood, February 15, 2005; 105(4): 1566 - 1573.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Xiang, N. Mizutani, Y. Luo, C. Chiodoni, H. Zhou, M. Mizutani, Y. Ba, J. C. Becker, and R. A. Reisfeld
A DNA Vaccine Targeting Survivin Combines Apoptosis with Suppression of Angiogenesis in Lung Tumor Eradication
Cancer Res., January 15, 2005; 65(2): 553 - 561.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. H. Andersen, I. M. Svane, P. Kvistborg, O. J. Nielsen, E. Balslev, S. Reker, J. C. Becker, and P. t. Straten
Immunogenicity of Bcl-2 in patients with cancer
Blood, January 15, 2005; 105(2): 728 - 734.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
M. E. Johnson and E. W. Howerth
Survivin: A Bifunctional Inhibitor of Apoptosis Protein
Vet. Pathol., November 1, 2004; 41(6): 599 - 607.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. H. Andersen, J. Fensterle, S. Ugurel, S. Reker, R. Houben, P. Guldberg, T. G. Berger, D. Schadendorf, U. Trefzer, E.-B. Brocker, et al.
Immunogenicity of Constitutively Active V599EBRaf
Cancer Res., August 1, 2004; 64(15): 5456 - 5460.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Lu, Y. Mu, C. Cao, F. Zeng, S. Schneider, J. Tan, J. Price, J. Chen, M. Freeman, and D. E. Hallahan
Survivin As a Therapeutic Target for Radiation Sensitization in Lung Cancer
Cancer Res., April 15, 2004; 64(8): 2840 - 2845.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. M. Coughlin, B. A. Vance, S. A. Grupp, and R. H. Vonderheide
RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy
Blood, March 15, 2004; 103(6): 2046 - 2054.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Nagorsen, C. Scheibenbogen, F. M. Marincola, A. Letsch, and U. Keilholz
Natural T Cell Immunity against Cancer
Clin. Cancer Res., October 1, 2003; 9(12): 4296 - 4303.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Casati, P. Dalerba, L. Rivoltini, G. Gallino, P. Deho, F. Rini, F. Belli, D. Mezzanzanica, A. Costa, S. Andreola, et al.
The Apoptosis Inhibitor Protein Survivin Induces Tumor-specific CD8+ and CD4+ T Cells in Colorectal Cancer Patients
Cancer Res., August 1, 2003; 63(15): 4507 - 4515.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. M. Schmidt, K. Schag, M. R. Muller, M. M. Weck, S. Appel, L. Kanz, F. Grunebach, and P. Brossart
Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells
Blood, July 15, 2003; 102(2): 571 - 576.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
A. Admon, E. Barnea, and T. Ziv
Tumor Antigens and Proteomics from the Point of View of the Major Histocompatibility Complex Peptides
Mol. Cell. Proteomics, June 1, 2003; 2(6): 388 - 398.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
J. E. Celis, P. Gromov, I. Gromova, J. M. A. Moreira, T. Cabezon, N. Ambartsumian, M. Grigorian, E. Lukanidin, P. thor Straten, P. Guldberg, et al.
Integrating Proteomic and Functional Genomic Technologies in Discovery-driven Translational Breast Cancer Research
Mol. Cell. Proteomics, June 1, 2003; 2(6): 369 - 377.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Zeis, S. Siegel, A. Wagner, M. Schmitz, M. Marget, R. Kuhl-Burmeister, I. Adamzik, D. Kabelitz, P. Dreger, N. Schmitz, et al.
Generation of Cytotoxic Responses in Mice and Human Individuals Against Hematological Malignancies Using Survivin-RNA-Transfected Dendritic Cells
J. Immunol., June 1, 2003; 170(11): 5391 - 5397.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. R. Wall, D. S. O'Connor, J. Plescia, Y. Pommier, and D. C. Altieri
Suppression of Survivin Phosphorylation on Thr34 by Flavopiridol Enhances Tumor Cell Apoptosis
Cancer Res., January 1, 2003; 63(1): 230 - 235.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Schrama, E. Fuchs, E.-B. Brocker, P. thor Straten, and J. C. Becker
Identical T-cell Receptor Transcripts in Multiple Melanoma Metastases
Cancer Res., October 15, 2002; 62(20): 5664 - 5667.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X.-F. Yang, C. J. Wu, L. Chen, E. P. Alyea, C. Canning, P. Kantoff, R. J. Soiffer, G. Dranoff, and J. Ritz
CML28 Is a Broadly Immunogenic Antigen, Which Is Overexpressed in Tumor Cells
Cancer Res., October 1, 2002; 62(19): 5517 - 5522.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Hirohashi, T. Torigoe, A. Maeda, Y. Nabeta, K. Kamiguchi, T. Sato, J. Yoda, H. Ikeda, K. Hirata, N. Yamanaka, et al.
An HLA-A24-restricted Cytotoxic T Lymphocyte Epitope of a Tumor-associated Protein, Survivin
Clin. Cancer Res., June 1, 2002; 8(6): 1731 - 1739.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Jager, R. Salter, C. Castelli, H. Hohn, K. Freitag, J. Karbach, C. Neukirch, A. Necker, A. Knuth, and M. J. Maeurer
Impact of Antigen Presentation on TCR Modulation and Cytokine Release: Implications for Detection and Sorting of Antigen-Specific CD8+ T Cells Using HLA-A2 Wild-Type or HLA-A2 Mutant Tetrameric Complexes
J. Immunol., March 15, 2002; 168(6): 2766 - 2772.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.